BHCM
ATYR

Brevan Howard Capital Management’s aTyr Pharma ATYR Stock Holding History

Brevan Howard Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-234,613
Closed -$169K – 2350
2025
Q3 		$169K Buy
+234,613
New +$1.06M ﹤0.01% 1785
2025
Q2 		– Sell
-53,209
Closed -$161K – 2046
2025
Q1 		$161K Buy
+53,209
New +$194K ﹤0.01% 1015

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brevan Howard Capital Management's ATYR Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 234,613 shares — an estimated $169K sold.

Brevan Howard Capital Management first reported a position in ATYR in Q1 2025 and held it in 2 quarters. The position peaked at $169K in Q3 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 234,613 aTyr Pharma shares in Q4 2025, an estimated $169K.
  • Brevan Howard Capital Management first reported a position in aTyr Pharma in Q1 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's aTyr Pharma position peaked at $169K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.